Log in

TSE:CPHCipher Pharmaceuticals Stock Price, Forecast & News

C$1.22
+0.04 (+3.39 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
C$1.18
Now: C$1.22
C$1.22
50-Day Range
C$1.14
MA: C$1.21
C$1.31
52-Week Range
C$0.38
Now: C$1.22
C$1.68
Volume14,100 shs
Average Volume47,788 shs
Market CapitalizationC$32.98 million
P/E Ratio6.49
Dividend YieldN/A
BetaN/A
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.
Read More
Cipher Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-6025840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$23.21 million
Cash FlowC$0.34 per share
Book ValueC$1.14 per share

Profitability

Miscellaneous

Employees39
Market CapC$32.98 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive CPH News and Ratings via Email

Sign-up to receive the latest news and ratings for CPH and its competitors with MarketBeat's FREE daily newsletter.

Cipher Pharmaceuticals (TSE:CPH) Frequently Asked Questions

How has Cipher Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cipher Pharmaceuticals' stock was trading at C$0.74 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CPH shares have increased by 64.9% and is now trading at C$1.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cipher Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cipher Pharmaceuticals.

When is Cipher Pharmaceuticals' next earnings date?

Cipher Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Cipher Pharmaceuticals.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (TSE:CPH) issued its quarterly earnings data on Thursday, May, 7th. The company reported $0.13 EPS for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.07. The company earned $7.92 million during the quarter, compared to analyst estimates of $7.05 million. View Cipher Pharmaceuticals' earnings history.

What price target have analysts set for CPH?

2 brokers have issued twelve-month price targets for Cipher Pharmaceuticals' stock. Their forecasts range from C$1.50 to C$1.50. On average, they expect Cipher Pharmaceuticals' share price to reach C$1.50 in the next year. This suggests a possible upside of 23.0% from the stock's current price. View analysts' price targets for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

Headlines about CPH stock have trended negative this week, InfoTrie reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cipher Pharmaceuticals earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

What other stocks do shareholders of Cipher Pharmaceuticals own?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the following people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Mr. Norman Evans, Consultant (Age 64)

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CPH."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPH stock can currently be purchased for approximately C$1.22.

How big of a company is Cipher Pharmaceuticals?

Cipher Pharmaceuticals has a market capitalization of C$32.98 million and generates C$23.21 million in revenue each year. Cipher Pharmaceuticals employs 39 workers across the globe.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is www.cipherpharma.com.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.

This page was last updated on 7/12/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.